🟢 87/100

This product is generally safe

  • Niacin: 500mg is 14.3× the Tolerable Upper Intake Level (35mg)
  • 100% of ingredients have research evidence
C Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Niacin: 500mg is 14.3× the Tolerable Upper Intake Level (35mg)

Label Data

2 Tablet(s) Serving Size
60 Servings
Other Combinations Product Type
100% Evidence Coverage

Supplement Facts — Evidence Check

500 mg (3125% DV)
⚠️ Exceeds Tolerable Upper Intake Level by 14.3× (UL: 35 mg) 📚 193 studies (Tier A: 5, B: 63)
RDA 14mg This product: 500mg UL 35mg
84 mg (20% DV)
📊 Market median: 4002.0mg (1 products) 📚 20 studies (Tier A: 0, B: 2)
This product: 84mg
📊 Market median: 4002.0mg (1 products) 📚 20 studies (Tier A: 0, B: 2)
This product: 1000mg

Other Ingredients

Vegetable Wax Stearic Acid Magnesium Stearate Silica

Label Claims — Verification

Nutrient
All Other
Structure/Function
All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Adult (18 - 50 Years) Sugar Free

Product Information

📋 Directions for Use

Suggested Use: Take two (2) tablets daily with a full glass of water, preferably with a meal, or as directed by your healthcare practitioner.

⚠️ Warnings & Precautions

Consult your healthcare professional prior to use if you have or suspect a medical condition, are taking any medications, or are pregnant or nursing.

Keep out of reach of children.

Do not use if seal is broken or missing.

🧪 Formulation Notes

Magtein & Niacinamide

No salt, sugar, starch, preservatives, artificial color or flavorings.

Additional Information

Store in a cool, dry place.

Natural color variation occurs in tablets. Formulated for steady release over 3–5 hours.

Sustained release

Promotes brain health and cellular energy

500mg/250mg

17512

Product Details

UPC / SKU 7 29135 17512 3
DSLD Entry Date 2018-07-25
Product Type Other Combinations
Form Tablet or Pill
DSLD ID 177814
Data Updated 2026-04-11

Research Evidence

241 Research Sources
55 Avg Quality Score
113 Meta Analysis
75 Systematic Review
32 Rct
11 Clinical Trial
3 Other
3 Regulatory Source
1 Cochrane Review
1 Narrative Review
1 Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016
View all evidence for Niacin →

Compare Similar Products

View all Niacin products →